Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VistaGen Therapeutics Inc.

www.vistagen.com

Latest From VistaGen Therapeutics Inc.

VistaGen Stocks Neuropsychiatry Pipeline And Takes Aim At Depression Market

Shawn Singh, CEO of VistaGen, a growing Silicon Valley-based biotech focused on psychiatry and neurological drug development, outlines the company’s strategy for getting to market in the US and expanding its pipeline into new areas.

Leadership Research and Development Strategies

Deal Watch: Cigna Acquisition Of Express Scripts OKed By US Justice Dept.

It remains unclear what impact the consolidation within the drug-distribution sector may have on pricing. Pfizer partners with France’s Cytoo for its new gene therapy approach to DMD, while Gilead teams with Precision BioSciences for its goal to cure HBV.

Deals Business Strategies

Tech Transfer Roundup: Mustang Licenses St. Jude’s Gene Therapy For Bubble Boy Disease

Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.

Deals Intellectual Property

Pipeline Watch: Phase III Starts With Enzastaurin, Sparsentan And Abaloparatide

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • VistaGen Therapeutics Inc.
  • Senior Management
  • Shawn K Singh, CEO
    Jerrold D Dotson, VP, CFO & Secretary
    H. Ralph Snodgrass, PhD, Pres. & CSO
    Mark A Smith, MD, PhD, CMO
    Mark A McPartland, VP, Corp. Dev.
  • Contact Info
  • VistaGen Therapeutics Inc.
    Phone: (650) 577-3600
    343 Allerton Ave.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register